Cambridge Drug Discovery, Parke-Davis Complete HTS Collaboration

Cambridge Drug Discovery Ltd. (Cambridge, UK) and Parke-Davis Neuroscience Research Centre (NRC; Cambridge, UK) have successfully completed a high-throughput screening (HTS) program to identify novel compounds at a receptor target associated with pain. The collaborative program utilized one of the NRC's established assays for high-throughput quantitative pharmacology.

According to Nirmala Suman-Chauhan, senior group leader of screening/assay development at Parke-Davis NRC, the collaborative effort provided Parke-Davis with some potentially important compounds for pain management. The company is now studying their chemistry in greater detail.

Parke-Davis is a multinational pharmaceutical company that offers innovative, high-quality products to advance the health and well being of people around the world. The company's major brands include Ponstan, Accupril, Accuretic, Tilazem, Epanutin, Demetrin, Chloromycetin, Lopid, Ketalar, and Valoron.

On January 4, 2000, Cambridge Drug Discovery Ltd. merged with Cambridge Genetics Ltd. to form a new company that provides drug discovery solutions to the pharmaceutical and biotechnology industries. The company's platform strength stems from its target discovery, assay development, efficient high-throughput screening, and integrated informatics capabilities that it exploits to enhance its partners' drug discovery programs.

For more information: Barry Kenny, Research Director, Cambridge Drug Discovery Ltd., Cambridge Science Park, Milton Rd., Cambridge, CB4 0FG, UK. Tel: +44 1223-723-222. Fax: +44 1223-723-223. Nirmala Suman-Chauhan, Senior Group Leader, Screening/Assay Development, Parke-Davis Neuroscience Research Centre, Cambridge University Forvie Site, Robinson Way, Cambridge, CB2 2QB, UK. Tel: +44 1223-210-929. Fax: +44 1223-249-106.

Edited by Jim Pomager